JP2022528030A5 - - Google Patents
Info
- Publication number
- JP2022528030A5 JP2022528030A5 JP2021539880A JP2021539880A JP2022528030A5 JP 2022528030 A5 JP2022528030 A5 JP 2022528030A5 JP 2021539880 A JP2021539880 A JP 2021539880A JP 2021539880 A JP2021539880 A JP 2021539880A JP 2022528030 A5 JP2022528030 A5 JP 2022528030A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- fusion protein
- protein according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789212P | 2019-01-07 | 2019-01-07 | |
| US62/789,212 | 2019-01-07 | ||
| PCT/US2020/012624 WO2020146423A1 (en) | 2019-01-07 | 2020-01-07 | Multi-functional fusion proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528030A JP2022528030A (ja) | 2022-06-08 |
| JP2022528030A5 true JP2022528030A5 (https=) | 2022-12-26 |
| JP7587505B2 JP7587505B2 (ja) | 2024-11-20 |
Family
ID=71521906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539880A Active JP7587505B2 (ja) | 2019-01-07 | 2020-01-07 | 多機能性融合タンパク質及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12497439B2 (https=) |
| EP (1) | EP3908664A4 (https=) |
| JP (1) | JP7587505B2 (https=) |
| KR (1) | KR20220025698A (https=) |
| CN (1) | CN113518823B (https=) |
| AU (1) | AU2020207265B2 (https=) |
| BR (1) | BR112021013415A2 (https=) |
| CA (1) | CA3125748A1 (https=) |
| IL (1) | IL284679A (https=) |
| MX (1) | MX2021008207A (https=) |
| SG (1) | SG11202107454UA (https=) |
| WO (1) | WO2020146423A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EP3908664A4 (en) | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| CN116261567A (zh) * | 2020-07-03 | 2023-06-13 | 纽约市哥伦比亚大学理事会 | 多功能性正交蛋白嵌合体 |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| WO2022188129A1 (zh) * | 2021-03-12 | 2022-09-15 | 利时雨 | 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用 |
| AU2023253516A1 (en) * | 2022-04-15 | 2024-11-21 | Imbiologics Corp. | Fusion protein platform with improved half-life |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220482A1 (en) | 2000-02-03 | 2003-11-27 | Ziwei Huang | Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II |
| WO2002022687A2 (en) | 2000-09-15 | 2002-03-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral chemokine-tumur antigen fusion proteins |
| CA2448109A1 (en) | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| JP2018516969A (ja) * | 2015-06-12 | 2018-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 |
| CA3004804A1 (en) * | 2015-11-17 | 2017-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| US20200093789A1 (en) | 2017-05-10 | 2020-03-26 | The General Hospital Corporation | Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor |
| EP3626266A4 (en) * | 2017-05-16 | 2021-04-07 | Jiangsu Hengrui Medicine Co., Ltd. | CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| AR112257A1 (es) * | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| EP3908664A4 (en) | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
-
2020
- 2020-01-07 EP EP20738361.3A patent/EP3908664A4/en active Pending
- 2020-01-07 JP JP2021539880A patent/JP7587505B2/ja active Active
- 2020-01-07 MX MX2021008207A patent/MX2021008207A/es unknown
- 2020-01-07 WO PCT/US2020/012624 patent/WO2020146423A1/en not_active Ceased
- 2020-01-07 CA CA3125748A patent/CA3125748A1/en active Pending
- 2020-01-07 AU AU2020207265A patent/AU2020207265B2/en active Active
- 2020-01-07 BR BR112021013415A patent/BR112021013415A2/pt unknown
- 2020-01-07 US US17/421,053 patent/US12497439B2/en active Active
- 2020-01-07 SG SG11202107454UA patent/SG11202107454UA/en unknown
- 2020-01-07 CN CN202080016520.5A patent/CN113518823B/zh active Active
- 2020-01-07 KR KR1020217024898A patent/KR20220025698A/ko active Pending
-
2021
- 2021-07-07 IL IL284679A patent/IL284679A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022528030A5 (https=) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7356970B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2024023317A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2023523628A5 (https=) | ||
| JP2019514846A (ja) | 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用 | |
| JP2022527081A5 (https=) | ||
| AU2020308463A1 (en) | Antibodies for T-cell activation | |
| JP2023547506A5 (https=) | ||
| US20240156863A1 (en) | Sequential anti-cd19 therapy | |
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| JP2024535740A5 (https=) | ||
| RU2021121848A (ru) | Многофункциональные слитые белки и их применения | |
| CA3250429A1 (en) | MODIFIED CYTOXIC T LYMPHOCYTES AND ASSOCIATED METHODS OF USE | |
| RU2024106039A (ru) | Многофункциональные слитые белки и их применения | |
| Shuptrine et al. | Bifunctional antibodies: preclinical and clinical applications | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof |